Drug or technology

Angiotensin Receptor Antagonists

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 1, 2026 · JOURNAL ARTICLE

Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: Insights from the PREMIER study.

American Heart Journal

Post hoc exploratory subanalysis of a parent RCT using a calculated variable (estimated total blood volume) to interrogate heterogeneity in a biomarker endpoint; the authors explicitly state findings are hypothesis-generating and require external validation.

Hypothesis-GeneratingAtsushi Tanaka Stroke Volume Angiotensin-converting Enzyme Inhibitors

Reported

Sample size analyzed372

TBV median dichotomization point4.05 L

NT-proBNP proportional change hig…-56%

APR 7, 2026 · JOURNAL ARTICLE

Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025).

Renal Failure

This is a bibliometric analysis of published literature, not a primary clinical study, and provides no original outcome data on sacubitril/valsartan efficacy or safety.

Insufficient InformationCardiorenal Syndrome Baihai Su Chronic Kidney Disease

Reported

Sample size254

US betweenness centrality0.33